Foto del docente

Mariacristina Di Marco

Assistant professor

Department of Experimental, Diagnostic and Specialty Medicine - DIMES

Academic discipline: MED/06 Medical Oncology

Curriculum vitae

Education

  • MD with honors in Surgery and Medicine, University of Bologna, Bologna, Italy, 26 June 1997
  • Specialization in Oncology , University of Bologna, Bologna, Italy, 15 November 2001
  • Research Doctorate in Experimental and Clinical Oncology, University of  Modena and Reggio Emilia, Italy, 18 March 2005.

ACADEMIC/SCIENTIFIC EXPERIENCE 

·        Student at the Institute of Clinical Medicine of the University of Bologna from December 1994 under the guidance of Prof. G. Biasco, until graduation in June 1997: in this period attendance in the Laboratory of Gastrointestinal Histopathology, carried out mutagenicity studies on gastric juices through the Ames test, in collaboration with Prof. Patrizia Hrelia, Pharmacist of the University of Bologna, studies with the scanning electron microscope on biopsies of the gastric cavern of the body, microbiology studies of the bacterial flora of the gastric juices, under the supervision of Dr. G. Brandi

·        Medical intern in Oncology in November 1997, continued to attend the Institute of Clinical Medicine of the University of Bologna until September 1998, until together with Prof. G. Biasco and his group transferred to Institute of Hematology and Medical Oncology L. e A. Seragnoli, Director Prof. S. Tura

·        Winner of “Ugo ed Evaristo Stefanelli” Scholarship in the academic year 1998/99 for the University of Bologna for presenting the study on “Evaluation of the efficacy and toxicity of  carboplatin and paclitaxel in advanced NSCLC”

·        Winner of a Scholarship from the Health Authority of the Sant'Orsola-Malpighi Hospital of Bologna for research on “Biomolecular targets of colorectal cancer risk” carried out from 26 November 2001 to 25 November 2002 at the Institute of Hematology and Medical Oncology L. e A. Seragnoli,

·        From June 2003 – December 2004, January 2004 – April 2004, May 2004 – December 2004, January 2005 – June 2005 carried out clinical and research activity, in particular on Chemoprophylaxis for Colorectal Cancer with Lipoic Acid and Folic Acid (MURST program ex-40%) care of the Institute of Hematology and Medical Oncology L. e A. Seragnoli, Health Authority of the Sant'Orsola-Malpighi Hospital with a renewable freelance contract

·        From July 2005 – December 2005, January 2006 – April 2006, May 2006 – September 2006 carried out clinical and research activity in a multicenter study: “Randomized, double blind, placebo controlled, multicentric phase III trial to evaluate the efficacy and the safety of adding Bevacizumab to Gemcitabine and Erlotinib in patients with metastatic pancreatic cancer” at the Institute of Hematology and Medical Oncology L. e A. Seragnoli, Health Authority of the Sant'Orsola-Malpighi Hospital with a renewable freelance contract

·        From 1 October 2006 employed by the University of Bologna in the role of Researcher in the Oncology Disciplinary Department MED/06.

·        From 1 October 2006 to present, carries out research and clinical assistance care of SSD Oncology Prof. Biasco in connection with the Department of Hematology and Oncology Science L. e A. Seragnoli, Health Authority of the Sant'Orsola-Malpighi Hospital.

Training and Refresher Courses

English Language: received the English Diploma (Level C1) from the British Institutes, 8 November 2004

  • Medical License in Medicine : 15 December 1997
  • Diploma in Oncology: 15 November 2001 with the thesis titled, New ways of treatment of colorectal cancer: implications to clinical pratice”
  • Doctorate in Research in Experimental and Clinical Oncology : 18 March 2005

 

 

EDUCATIONAL ACTIVITIES

 

 

·        Academic years 1999/2000 and 2000/2001: Organizer of Seminars in Oncology at the Università di Bologna, with Prof. G. Biasco

·        Academic years 2003/2004, 2004/2005 and 2005/2006: Teaching assistant for students in the Oncology Course in the area for the Degree Program for Orthopedic Technicians and for the Degree Program for Physiotherapists at the Università di Bologna

·        1 October 2006 to present teaching position on the Faculty of Medicine and Surgery of Bologna, in particular teaching in Oncology and primary responsibility for the integrated course of Special Rehabilitation II in the field of CDL Physiotherapy

·        1 November 2006 to present Teaching position in the area of D. Medical Oncology for the School of Specialization in Oncology for the University of Bologna.

·        Scientific Coordinator for the Università di Bologna for the project “Distance Training in Oncology (FADO) for the Consorzio Interuniversitario Nazionale for  Bio-Oncology in the period from January – February 2007

·        Academic years 2006/2007 and 2007/2008 Teaching assistant for students in the Medical Degree program for the  preparation of  the thesis

·        Academic years 2006/2007 and 2007/2008 Teaching assistant for students in the School of Specialization in Oncology.

·         

 

Official invitations to present relations at the following national scientific meetings:

 

 

·        Was selected to present in the poster session “Colorectal Gastro-intestinal Tumors” the work “New therapeutic strategies in advanced colon rectal cancer: our clinical experience” at the 3rd  National Congress of Medical Oncology held in Naples 4-7 November 2001

·        Called to give a presentation in the training course “Tumors of the head and neck: nosologico placement” held in Bologna 23 November 2005

·        Was selected to present in the poster session in 2006 at the World Congress on Gastrointestinal cancer, held in Barcelona 28 June – 01 July, “Effect of folate and alphalipoic acid supplementation on rectal mucosal cells kinetics.”

·        Speaker at the Convention of 6-7 October 2006 held in Matera for the Congress “Tumors of the pancreas and the acute pancreatitis”, with a paper titled “Target Therapies”

·        Scientific Coordinator for the Università di Bologna for the project “Distance Training in Oncology (FADO) for the Consorzio Interuniversitario Nazionale for  Bio-Oncology in the period from January – February 2007

·        Speaker for the Mediterranean School of Oncology al “Highlights in management of gastrointestinal cancer”, 11-12 April 2008, Rome with the paper ”Progresses in the treatment of the pancreatic cancer”.

·          Called to present a Poster and speak at the 32nd National Congress for the Italian Association for the Study of the Pancreas (A.I.S.P.), Montecatini Terme, 2-4 October 2008

 

 

Participation in National and International scientific Projects and in teaching

 

 

·        1998: took part in the local Organization Committee of the International ConferenceGastric Cancer from chemoprevention to chemotherapy” held in Bologna on 16-17 April

·        1998 : took part on the Editorial Committee, under the direction of Prof. G. Biasco, of the periodical “Medical Science Bulletin”, Newsletter of the Medical-Surgical School of Bologna (January-December)

·        2004: was nominated for Scientific Secretary for the Scientific meeting “Oral Chemotherapy in Oncology”, held in Bologna 4 May.

·        2005: Coordinator and Speaker of the training course “Brain Tumors, melanoma, tumors of the head and neck” held in Bologna 21-23 November 2005

·        2006: Scientific Secretary and Speaker of the scientific meeting “Cancer of the pancreas: clinical update” Bologna, 16 June 2006

·        2006: Coordinator of the training course “Support therapy in Oncology”, Bologna 26-28 June 2006

Conventions, Training and Refresher Courses

 

The Formative Credits obtained starting from June 2002 to today are a total of 366 .

Courses participation about 80.

 

 

RESEARCH PROJECTS

 

Participation in various research projects (ex 40% and ex 60%) financed by MIUR, which are listed below by year, research title and responsibilities:

§           2001 : “Biological and ultrastructural alterations and risk of cancer of the duodenum in the familial adenomatous polyposis” with Clinical Analysis responsibility ;

§           19 April 2002 : “Effect of the administration of antioxidant and folic acid on the cellular  proliferation of the epithelial cells of the rectum in subjects at risk for colon cancer” with the responsibility of selecting patients and the Analysis of Cellular Kinetics;

§           14 May 2003 : “Biological prognosis factors of colon cancer and the therapeutic implications” with the responsibility of Elaborating the data;

§            14 December 2007: “Over expression of the tissutale transglutaminase and the implications of multidrug resistance in pancreas cancer”.

 

In addition, participation in various national and international spontaneous clinical and multicenter trials in the role of  co-investigator carrying out 17 studies in many fields

 

Clinical Oncology

 

Stomach Cancer

 

Lung Carcinoma

 

Support therapy: treatment for emesis

 

Biological alterations, ultrastructural and risk of cancer of the duodenum in FAP

 

Chemoprophylaxis for cancer

 

Colon Cancer

 

Oral Fluoropyrimidine

 

Advanced Melanoma

 

GIST (gastrointestinal stromal tumor)

 

Prognosis factors of colon cancer

 

 

Pancreas cancer

 

 

MOVED FROM ABOVE:

a)        “Fase II Study   with Carboplatin  and Paclitaxel in patients advanced NSCLC ”, (1998)

b)        Multycenter study: “Subcutaneous IL-II + NSAIDs treatment in advanced NSCLC patients”,(1999);

c)        Multicenter study: “RP64174A-V-307: Multicenter , Phase III, Open Label, Randomized Trial Comparing CPT-11 in Combination with a 5-FU/FA Infusional Regimen to the same 5-FU/FA Infusional Regimen Alone as Adjuvant Treatment of Stage II and III Colon Cancer”;

d)        Fase II multicenter study “Temozolomide and interferon-alpha in metastatic melanoma: a phase II study on the Italian Melanoma Intergroup”,( 2000);

e)        Multicenter  study: “Double-Blind Clinical Study to Compare Single IV Doses of Palonosetron, 0.25 mg or 0.75 mg, and Ondansetron, 32 mg IV, in the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting”, prot. N° PALO-99-03, ( 2000);

f)           Multicenter study : “Double-Blind Clinical Study to Compare Single IV Doses of Palonosetron, 0.25 mg or 0.75 mg, and Ondansetron, 32 mg IV, in the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting”, prot. N° PALO-99-05, ( 2000);

g)        Multicenter study “A multicenter, Open-Label study to assess the Safety and Efficacy of IV Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Repeated Chemotherapy Cycles”, prot. N° PALO-99-06, ( 2000);

h)        Spontaneus study: “Effects of  antioxidants and  folic acid on rectal epitelial cells proliferation in patient with  risck of colon cancer ”, (program MIUR ex 40%),  2002;

i)          Pilot  study:The chemopreventiv effects of alfa lipoic acid in patients whith colon  cancer risk , (2002);

j)          Multicenter study: “Phase III, Randomized Double-Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients with Imatimib Mesylate (Gleevec, Glivec)-Resistant or Intolerant Malignant Gastrointestinal Stromal Tumor”;

k)        Multicenter study “Epidemiology in oncology emesis treatments”, ( 2004);

l)          Open fase III multicenter randomized trial, of adjuvant chemotherapy for gastric cancer radicaly operated:  (CPT-11 + 5FU/LV è TXT + CDDP) vs.  5-FU/LV regimen, protocollo IRFNEGR III, 2004, 003, (2005);

m)      International multicenter study : “Randomized, double blind, placebo controlled, multicentric phase III trial to evaluate the efficacy and the safety of adding Bevacizumab to Gemcitabine and Erlotinib in patients with metastatic pancreatic cancer”, (2005)

n)        International multicenter trial: “A phase IIIB study of Tarceva (Erlotinib) in patients with locally advanced, unresectable or metastatic pancreatic cancer”, accettato dal (2007);

o)        Prospectic randomized trial about neoadjuvant chemoradioterapy with surgery alla vs. surgery alone in patients with resctable pancreatic adenocarcinoma, in collaborations with  NEOPAN gruop (Surgery, Radioterapy, Internal Medicine) of S'Orsola-Malpighi Hospital (2007).

p)        Multicenter international study: “A randomized, double blind phase III study og Gemcitabine plus AG-013736 versus Gemcitabine plus placebo for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer”, accettato dal comitato etico il 18 dicembre (2007);

q)        National multicenter study promoted by GISCAD Foundation cancer reserch: “Fase II randomized with Gemcitabin/Cisplatinwith or without  Sorafenib for evaluate the efficacy and safety of tratement in patients local advanced pancreatic cancer or metastatic cancer.  MAPS Study. (2008).

The reserche fields and scientific products was  firstly about Clinical Oncology. Recently was

concentrated on Gastrointestinal cancer in particular chemoprevention area and in pancreatic cancer treatment, as demonstrate the last forum and courses partecipationsions as relators.

Pubblications 33 since 1998 to 2008

 

1.      S. Tamberi, P. Mordenti, B. Poggi, MC Di Marco, S. Casadei, R. Bazzocchi, G. Biasco. “Carboplatin (CBDCA) and Paclitaxel (TAX) in advanced non small cell lung cancer (NSCLC): preliminary results”. Tumori, 1998; Vol. 84, suppl. 1, n° 5: p. 93 (abstract 239);

 

2.      G. Biasco, MC Di Marco. “Esofago di Barret”. Capitolo del testo “Malattia da reflusso gastro-esofageo”, a cura di G. Ferrini, 1999: pp. 63-69;

 

3.      S. Tamberi, E. Gallerani, R. Bazzocchi, M. Zompatori, G. Martinelli, M. Schiavina, MC Di Marco, G. Brandi, G. Biasco. “Carboplatin (CBDCA) and Paclitaxel (TAX) as induction chemoterapy in stage IIIA- IIIB in non small cell lung cancer (NSCLC)”. The European Journal of Cancer, 1999; Vol. 35, Suppl. 4: p. 264 (abstract 1052);

 

4.      Mordenti P., Poggi B., Casadei S., Di Marco MC, Tamberi S., Bonarelli S., Baroncini S., Biasco G. “Oxaliplatin (OHP) in advanced colorectal cancer (ACC): safety and Toxicity”. 1° Congresso Nazionale di Oncologia Medica, 1999; Roma, 24-28 Ottobre 1999; Vol. 1: p. 20 (abstract 60);

 

5.      Fabbri M., Casadei S., Di Marco MC, Ridolfi L., Albertini P., Riva N., Ibrahim T., Ridolfi R., Biasco G., Amadori D. “Subcutaneous IL-2 + NSAIDs treatment in advanced NSCLC patients: preliminary data on survival and lymphocytary immunodeficit”. 1° Congresso Nazionale di Oncologia Medica, 1999; Roma, 24-28 Ottobre 1999; Vol. 1: (abstract 280);

 

6.      G. Brandi, R. Manfredi, C. Calabrese, A. Pisi, G. Di Febo, MC Di Marco, M. A. Di Bari, G. Cenacchi. “HIV enteropaty: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiretroviral therapy and case report”. 7th European Conference on Clinical Aspects and Treatment of HIV-infection, Lisbon – Portugal, 23-27 Ottobre 1999; p. 172 (abstract 710);

 

7.      G. Biasco, MC Di Marco, R. Akim. “Chemioterapia adiuvante nei tumori del pancreas e delle vie biliari”. Tratto dal libro degli atti dell'VIII Giornata Monotematica Nazionale: “Trattamento multimodale dell'ittero meccanico nella malattia oncologica: indicazioni, limiti e prospettive”. Bologna, 12 novembre 1999;

 

8.      G. Biasco, MC Di Marco, R. Akim. “Trattamento “adiuvante” nei tumori del pancreas”. Tratto dal libro degli atti del Post graduate course. Terapie delle malattie del pancreas e dell'ipertensione portale. Sanremo, 9-11 aprile 2000;

 

9.      P. Mordenti, MC Di Marco, MA Pantaleo, E. Gallerani, G. Brandi, M. Di Battista, G. Biasco. “The Folfox-4 regimen: a mono institutional experience in advanced colo-rectal cancer (ACC)”. Annals of Oncology, 2001; Vol. 12, suppl. IV: p. 8 (Abstract A21);

 

10.  MC Di Marco, P. Mordenti, MA Pantaleo, E Gallerani, G. Brandi, B. Poggi, G. Biasco, M Di Battista. “New therapeutic strateg ies in advanced colo-rectal cancer: our clinical experience”. Annals of Oncology, 2001; Vol. 12, suppl. IV, (Abstract A43);

 

11.  MA Pantaleo, G. Brandi, E. Nobili, G. Cenacchi, C. Calabrese, M. Di Battista, MC Di Marco, G. Biasco. “Alterazioni biomolecolari e fenotipiche della mucosa duodenale e dei pazienti affetti da FAP”. Abstract 1° Congresso Nazionale COMU (Collegio Oncologi Medici Universitari), Castiglion della Pescaia (GR), 10-11 maggio 2002; p. 76-77;

 

12.  G. Brandi, M. Di Battista, J. Dabard, MA Pantaleo, E. Nobili, MC Di Marco, R. Hakim, G. Biasco. “Ruolo della flora batterica nella tossicità da CPT-11”. Abstract 1° Congresso Nazionale COMU (Collegio Oncologi Medici Universitari), Castiglion della Pescaia (GR), 10-11 maggio 2002; p. 78-79;

 

13.  G. Biasco, MC Di Marco, MA Pantaleo. “Chemoprevention of colorectal cancer”. The International Journal of Biological Markers, 2003; Vol. 18, n° 1: pp. 75-77;

 

14.  G. Biasco, MC Di Marco, E. Nobili. “La terapia orale è un vero vantaggio ?” Tumori, 2003; Vol. 2, n° 4: pp. 136-138.

 

15.  G. Biasco, G. Brandi, C. Calabrese, MA Pantaleo, A Morselli Labate, G Di Febo, MC Di Marco, R. Akim, A De Vivo. “Circadian variations of rectal cell proliferation in patients affected by metastatic colorectal cancer”. Abstract Journal of Tumor Marker Oncology, Summer 2003; Vol. 18, n° 3: p. 208 (abstract P25);

 

16.  G. Brandi, M.A. Pantaleo, C. Galli, A. Falcone, A. Antonuzzo, P. Mordenti, MC Di Marco, G. Biasco. “ Hypersensitivity reactions related to oxaliplatin (OHP)”. British Journal of Cancer , 2003; n° 89: pp. 477-481;

 

17.  M.A. Pantaleo, G. Brandi, E. Derenzini, S. Fanello, MC Di Marco, M. Di Battista, E. Nobili, G. Biasco. “Is adjuvant systemic chemotherapy after resection of metastases from colorectal cancer suitable?” Proc. ASCO 2004; Vol. 23, n° 3654, p 283;

 

18.  G. Brandi, C. Calabrese, M.A. Pantaleo, A. Morselli Labate, G. Di Febo, R. Hakim, A. De Vivo, MC Di Marco, G. Biasco. “Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer”. Cancer Letters, 2004; n° 208: pp. 193-196.

 

19.  G. Brandi, E. Derenzini, M.A. Pantaleo, M. Di Battista, M. Ravaioli, G. Ercolani, G.L. Grazi, S. Fanello, MC Di Marco, E. Nobili, R. Hakim, R. Poggi, E. Palmerini, G. Biasco. “Systemic adjuvant chemotherapy after resection of colorectal cancer metastasis”. Annals of Oncology, 2004; Vol. 15, Suppl. II, p. 66 (abstract E38);

 

20.  R. Ridolfi, A. Romanini, V. Chiarion Sileni, M. Michiara, M. Guida, G. Biasco, P. Poletti, L. Amaducci, M. Leoni, A. Ravaioli, co-authors L. Ridolfi, L. Fiammenghi, L. Ballardini, L. Tanganelli, R. Todeschini, R. Redelotti, V. Lorusso, MC Di Marco, R. Labianca. “Temozolomide and interferon-alpha in metastatic melanoma: a phase II study on the Italian Melanoma Intergroup”. Melanoma Research, 2004; n° 14: pp. 295-299.

 

 

21.  V. Scurti, D. Sichetti, E. Sasso, M. Romero, Eteo Working Group (…, MC Di Marco, …). “Prospective, multicenter, observational survey on antiemetic treatment in oncological patients”. 17th MSACC International Symposium “Supportive Care in Cancer”, Ginevra, Giugno 2005, p. 421 (Abstract 04-038);

 

22.  V. Scurti, D. Sichetti, M. Romero, Eteo Working Group (…, MC Di Marco, …). “Prospective, multicenter, observational analysis of 5-HT3 receptor antagonist antiemetic prescribing with different chemotherapy regiments”. JCO, Suppl. 23, n° 16S, part I of II, June 2005, p. 791S (Abstract 8253);

 

23.  G. Biasco, MC Di Marco. “Folate and prevention of colorectal cancer in ulcerative colitis”; European Journal of Cancer Prevention, 2005; 14: pp.395-398;

 

24.  M. Di Battista, G. Brandi, S. Dell'Arte, MA Pantaleo, S. Fanello, E. Derenzini, M. Astorino, R. Poggi, MC Di Marco, M. Pirazzini, V. Nappi, G. Altimari, S. Baroncini, G. Biasco. “Cost of management of completely implantable catheters (CIC) in patients treated for advanced colorectal cancer”. Annals of Oncology, Vol. 16, Suppl. 7, VII National Congress of Medical Oncology, 18-21 October 2005, Naples, Session D, vii 41, n° D3;

 

25.  G. Brandi, E. Derenzini, E. Nobili, MC Di Marco, MA Pantaleo, E. Palassini, S. Dell'Arte, R. Hakim, M. Di Battista, S. Fanello, GL Grazi, A. Cavallari, G. Biasco. “Impact of surgery and Chemotherapy on survival in cholangiocarcinoma”. Annals of Oncology, Vol. 16, Suppl. 7, VII National Congress of Medical Oncology, 18-21 October 2005, Naples, Session E, vii 50, n° E7.

 

26.  E. Derenzini, M. Di Battista, MC Di Marco, S. Dell'Arte, M. Astorino, S. Bertolini, G. Brandi, G. Biasco. “Il trattamento delle metastasi epatiche da cancro del colon retto”. Minerva Medica 2006, 97 n° 1: 107-119.

 

27.  MC Di Marco, R. Di Cecilia, M. Di Battista, E. Palmerini, E. Derenzini, R. Poggi, S. Fanello, M. Astorino, G. Biasco. “Effect of folate and alphalipoic acid supplementation on rectal mucosal cells kinetics.” Poster 153, Annals of Oncology, Suppl. 6: 2006 World Congress on Gastrointestinal cancer, Barcellona.

 

28.  Zanini N., Casadei R., Angelelli B., Di Marco MC, Serra C., Piscitelli L., Minni F. “Locally advanced pancreatic cancer: is there a role for neoadjuvant chemo-radiation ? A case report and literature review.”, XXX Congresso Nazionale Associazione Italiana per lo Studio del Pancreas, pag. 27, Milano 21-23 settembre 2006.

 

29.  M. Di Marco, E. Nobili, R. Di Cicilia, G. Brandi, S. Bertolini, E. Derenzini, S. Dell'Arte, R. Casadei, L. Calculli, G. Biasco. “GEMOX as first-line chemotherapy in advanced pancreatic cancer (APC): A monoinstitutional experience.”, Journal of Clinical Oncology, 2007 ASCO, 20 June 2007, Vol. 25, No 18S Part I of II, n° 15179.

 

30.  G. Brandi, E. Nobili, E. Capizzi, B. Corti, R. Di Cicilia, M. Di Marco, G. Biasco. “Mixed exocrine-endocrine pancreatic cancer producing alpha-fetoprotein”. Pancreas, Vol 37, Issue 2, 1 Agosto 2008.

 

31.  Brandi G., Di Cicilia R., Di Battista M., Nobili E., Astorino M., Di Marco M., Pantaleo M.A., Biasco G. Capecitabine (CAP) based regimens vs. infusional 5-FU/FA in metastatic colorectal cancer cost/effectiveness: the differences across the atlantic ocean. P65, ix132, Vol. 19 Suppl. 9 Annals of Oncology, Ottobre 2008.

32. Di Marco M., Macchini M., Di Cicilia R., Nobili E., BiascoG.: Gemox in advanced pancreatic cancer (APC):experience in 31 patients. Abstract, Poster and oral comunicazion AISP (Associazione Italiana Studio Pancreas) Montecatini Terme 02-04/10/2008 in press on Journal of Pancreas (JOP)

33 Di Cicilia R.,Macchini M., Di MarcoM., Nobili E, Calculli l.,Casadei R.,Biasco G.: Gemox in combination with Erlotinib(E) panreatic cancer (PC). Abstract, poster AISP (Associazione Italiana Studio Pancreas) Congress Montecatini Terme 02-04/10/2008

32. Di Marco M., Macchini M., Di Cicilia R., Nobili E., BiascoG.: Gemox in advanced pancreatic cancer (APC):experience in 31 patients. Abstract, Poster and oral comunicazion AISP (Associazione Italiana Studio Pancreas) Montecatini Terme 02-04/10/2008 in press on Journal of Pancreas (JOP)

33 Di Cicilia R.,Macchini M., Di MarcoM., Nobili E, Calculli L.,Casadei R.,Biasco G.: Gemox in combination with Erlotinib(E) panreatic cancer (PC). Abstract, poster AISP (Associazione Italiana Studio Pancreas) Congress Montecatini Terme 02-04/10/2008

Latest news

At the moment no news are available.